We’re developing the first drugs explicitly intended to extend healthspan and lifespan—first in dogs, and then in humans, too.
By quantifying and controlling the mechanisms of pathological aging, we hope to delay the onset & reduce the severity of age-related diseases. More, healthier years.
Backed by the best
Our mission is supported by world-class funds and investors.
Our first products to market are focused on longevity and healthspan in dogs. Discover Loyal.
Wally
Tibetan Mastiff
Helping dogs live longer, healthier lives
Dogs are our closest companions – in every sense of the word. We co-evolved with dogs and have shared our environment for tens of thousands of years. Understanding and treating pathological dog aging may help us learn more about human aging, too.
In the news
These scientists are working to extend the lifespan of pet dogs – and their owners
Do you want to live forever? Big Tech and the quest for eternal youth
“I work on dog lifespan extension.” | Celine Halioua for Heretics
Why your dog isn’t the age you think
Inside the 30 Under 30 List
Founder-led biotech is making space for ideas– and diverse leaders– where it didn’t exist before
Loyal raises $27M, aims to give dog owners more time with their pets
Why this San Francisco anti-aging drug startup thinks it’s barking up the right tree
Canine cancer biomarkers to be explored
A dog’s life can be longer, promises tech start-up
How Silicon Valley is helping dogs live longer– so humans can live longer too
Silicon Valley Wants Dogs to Live Longer So Humans Can, Too
Aging is one of the most impactful problems you can work on.
Work with some of the most dynamic and accomplished scientists, engineers, operators, and creatives in the industry, on problems that matter:
- Developing better ways to quantify the aging process
- Predictive modeling of aging trajectories
- Building robust longitudinal aging datasets
- Characterizing healthy versus pathological aging
- Commercializing aging drugs
Built by the best
Our team hails from the world’s leading companies and institutions.
Our team
152
Papers published
56
Clinical drug programs worked on
192
Years of research
54%
Women
Open roles